Close Menu

NEW YORK – Illumina said yesterday that it has partnered with Chinese molecular diagnostics firm AnchorDx to develop clinical oncology tests for the Chinese market.

Under the terms of the strategic collaboration, AnchorDx, based in Guangzhou in southern China, will use Illumina's MiSeqDx sequencing system to develop in vitro diagnostic cancer test kits and data analysis software. AnchorDx plans to develop genomic cancer tests that range from screening to diagnostic testing to treatment monitoring.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.